Freedom Bank Kazakhstan, a part of Freedom Holding Corp., a NASDAQ-listed finance and technology group, received the award in ...

FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...